Anocca AB

SÖDERTÄLJE, Sweden I November 26, 2024 I Anocca AB, a leading T-cell receptor-engineered T-cell (TCR-T) cellular therapeutics company, announces the submission of its first Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for a Phase I/II multi-asset umbrella trial, VIDAR-1. The VIDAR-1 programme will begin with ANOC-001, which targets mutant KRAS G12V, in patients with advanced pancreatic cancer. Subject to approval of the CTA, Anocca aims to initiate the study in Q2, 2025. ANOC-001 is the lead product from Anocca’s robust preclinical pipeline of TCR-T cell therapies. Reagan Jarvis, co-founder and Chief Executive Officer, commented, “This is an important milestone for Anocca, affirming the value of our unique cell biology R&D engine. Our approach integrates the systematic generation of validated TCR-T target maps from tumour-selective genetic sequences and supports the delivery of libraries of potent and highly specific therapeutic TCRs to leverage the diverse cancer target space. With our in-house cGMP facilities and gene-edited autologous TCR-T manufacturing capability we can efficiently and cost effectively develop new investigational products at scale. Our ambition is to grow our pipeline rapidly across the immense untapped target space for TCR-T cell therapies in solid tumours.” Hugh Salter, Chief Scientific Officer at Anocca, elaborated, “KRAS is an immensely important target in many cancer types, but has to date been challenging to address. KRAS mutations are a hallmark of PDAC, which is among the most difficult to treat cancers, and we believe TCR-T cell therapies and, in particular, our VIDAR-1 assets can be effective in addressing this target and providing a new solution in an indication with high unmet medical need.” About the VIDAR-1 clinical programme VIDAR-1 is designed as a multi-asset umbrella trial targeting oncogenic driver mutations in KRAS within pancreatic ductal adenocarcinoma (PDAC). It will investigate up to 20 patients per product, where each product is specific for a different combination of HLA and mutation, in a set of phase I/II studies. Phase I is planned for eight sites in four countries with additional countries and sites in phase II. Subject to approval of the CTA, the company plans to initiate first-in-human clinical studies in Q2, 2025. Patients will be eligible to enroll if they have a HLA and KRAS mutation matching an available product. About KRAS and PDAC Mutant KRAS is implicated in pancreatic, lung and colorectal cancers. G12V and G12D mutations in KRAS affect ~90% of pancreatic cancer patients. The five-year survival rate of patients with PDAC is less than 10% (1). Despite recent advances there are no definitive treatments for advanced patients at present (2). References 1. Rawla et al (2019). Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World J Oncol . 10(1):10–27. doi: 10.14740/wjon1166 2 . Hu & O’Reilly (2023). Therapeutic developments in pancreatic cancer. Nat Rev Gastroenterol Hepatol 21, 7–24 . doi: 10.1038/s41575-023-00840-w About Anocca Anocca is a fully integrated biopharmaceutical company that develops libraries of T-cell receptor-engineered T cell (TCR-T) therapies to redefine the treatment of solid tumours and other difficult to treat diseases, including infectious and autoimmune diseases. Its unique discovery engine uses programmable human cells to recreate and manipulate T cell immunity. This proprietary technology scales TCR-T cell therapy development, allowing the systematic generation of personalised treatments for the broadest patient populations. Anocca operates an advanced research and development infrastructure, underpinned by a custom software ecosystem, AnoccaOS, and in-house cGMP manufacturing and process development facilities. All Anocca’s therapeutic TCRs are novel discoveries from its platform and manufactured using non-viral gene editing technology at Anocca’s facilities in Sweden. SOURCE: Anocca

伦敦，2024年11月20日——全球领先的生命科学研发与生产服务商金斯瑞生物科技集团，在英国伦敦成功举办了其全球产业论坛的欧洲首秀。自2020年首次在旧金山摩根大通医疗保健大会期间亮相以来，金斯瑞全球产业论坛已在推动细胞和基因治疗（CGT）领域的发展中产生了深远影响。此番论坛首次移师欧洲，进一步彰显了金斯瑞致力于推动全球CGT产业发展、持续拓展国际合作的坚定承诺。 全球细胞基因治疗领域的 学术界、投资界和企业界领军人物齐聚论坛 “以患者需求为中心”是整个医药界谋求发展的底层逻辑，也是本届论坛举办的初衷。“我们所做的一切努力就是为细胞与基因治疗产业界搭建一个国际合作，开放共享的探讨平台，最终仍是为了满足患者需求。” 本次论坛的组织者，金斯瑞集团政府事务与企业传播副总裁陈曦在接受会前采访时表示。 本届论坛邀请到了来自全球各地的CGT学术界、企业界和投资界的领军人物，他们围绕“Unlock the Full Potential of Cell and Gene Therapies”这一主题，共同探讨细胞基因治疗最新突破、技术创新及未来发展，从全方位、多维度视角为行业高水平发展出谋划策，以造福更多患者。 论坛现场 论坛由金斯瑞集团欧洲区总裁吴盛博士主持。金斯瑞集团轮值CEO邵炜慧女士在为本次论坛致开幕辞时说：“我们在这个论坛中深刻地感受到，CGT的每一项进步和每一份努力，都是为了更好地满足患者需求。”她还强调，金斯瑞将继续在细胞和基因治疗领域加大创新力度，与全球的合作伙伴携手努力，为更多患者带来福祉。 金斯瑞集团轮值CEO邵炜慧女士发表开幕致辞 金斯瑞集团欧洲区总裁吴盛博士主持介绍了论坛 在主旨演讲环节，金斯瑞特别邀请了国际细胞与基因治疗学会（ISCT）主席、Kiji Therapeutics首席执行官Miguel Forte博士及基因治疗权威专家、Gemma Biotherapeutics 总裁兼首席执行官James M. Wilson博士。两位专家的深度分享不仅拓宽了与会者的专业视野，也为行业未来发展提供了宝贵的见解。 国际细胞与基因治疗学会（ISCT）主席、 Kiji Therapeutics首席执行官 Miguel Forte博士发表主旨演讲 Forte博士进行的《细胞与基因治疗的年度现状与未来展望》主题分享聚焦细胞治疗的变革潜力，深入探讨了基因编辑、体内疗法以及监管审批面临的挑战与机遇。他强调理解细胞疗法开发长期性的必要性和全球合作的重要性，并认为亟需推动系统可持续发展以适应全球监管模式变化，关注伦理考量，以及通过体内疗法和生物工程等新兴技术创新应对生产制造、监管和患者可及性方面的挑战。他还指出实现细胞疗法的广泛应用需要平衡创新与可持续性，呼吁同行共同努力，管理预期、降低成本，确保全球患者能够获得公平的治疗机会。 Gemma Biotherapeutics 总裁兼首席执行官 James M. Wilson博士发表主旨演讲 Wilson博士在《遗传医学发展中的罕见病案例研究》主旨演讲中提到，基因疗法之于罕见病意义重大，并解释了基因治疗产品的商业化挑战，以及实现合理定价和医生积极处方的重要性。Wilson博士认为，应重点关注以生物标志物为终点的致命性、精神类疾病，把各类资源整合到一个平台上以降低临床试验成本和加快试验进度，并强调需开发适合罕见病的商业模式，认为患者倡导和社交媒体对推动药物可及性和提升公众认知很重要，关注报销机制及在创新与卫生主管部门资源利用间取得平衡也很关键。 在本届论坛上，除了引人入胜的主旨演讲，主办方还精心策划了四大互动环节，包括三场圆桌对话：“细胞治疗的技术创新与前沿突破”、“基因疗法与mRNA疫苗研发的最新进展”，以及“细胞与基因疗法开发及生产中的CMC挑战”，以及一场题为“投资者洞见：细胞与基因治疗的未来展望”的炉边会谈。这些环节内容丰富，亮点频现，吸引了众多与会者的广泛关注与积极参与。 CAR-T药物在血液肿瘤领域取得的空前成功，让我们领略到细胞疗法的无限潜力。如何将其拓展至包括实体瘤、自身免疫性疾病等在内的有着更广泛患者群体的疾病领域，已经成为全行业的共同目标。在《细胞治疗的技术创新与前沿突破》圆桌讨论中，全球知名专注生物医药创新媒体BioCentury生物制药情报总监Stephen Hansen与传奇生物首席执行官黄颖博士、Atara Biotherapeutics董事会主席Pascal Touchon博士、邦耀生物首席执行官郑彪博士、Ori Biotech首席执行官兼执行董事Jason Foster和Anocca 首席执行官兼联合创始人Reagan Jarvis博士等业界大咖汇聚于此，分享了各自的精彩观点。 “细胞治疗的技术创新与前沿突破”圆桌讨论现场 他们从患者视角切入，强调了CAR-T疗法的卓越疗效，能够将患者无进展生存期（PFS）从传统的4-5个月显著延长至接近3年，但也面临诸多挑战，尤其是实体肿瘤靶点的可及性和患者接受度，现阶段应优先解决实体瘤靶点有限性问题。他们指出，开发更加友好、便于操作的CAR-T疗法对于提高患者接受度至关重要。同时，扩大生产能力、提升产品可及性和确保产品安全也是当务之急，与医疗中心的合作对于开发具有商业可行性的产品尤为关键。专家们认为，未来5-10年内，自动化和异体CAR-T疗法、体内细胞疗法有望得到广泛应用，目前已有的7种 CAR T 产品累计治疗了10,000例患者。 技术突破的推动下，基因治疗、mRNA疫苗领域均取得长足进步，应用范围日益扩大。然而，这类疗法生产制备复杂，特别是载体的选择、生产与优化，对其开发进程有着深远影响。在由Pinsent Masons律所（伦敦）合伙人兼欧洲和英国专利代理人Kristina Cornish主持的《基因疗法与mRNA疫苗研发的最新进展》专题讨论中，AstraZeneca高级科学家Deividas Pazeraitis、GENYO首席研究员Karim Benabdellah博士、Sanofi科学家Maelle Quere博士、金斯瑞新型医药材料研发总监Lumeng Ye博士、Cell and Gene Therapy Catapult首席技术科学家Vincenzo Di Cerbo博士等在一线科研学者们深入探讨了基因编辑临床应用的技术趋势与创新动态。 “基因疗法与mRNA疫苗研发的最新进展”圆桌讨论现场 议题涵盖病毒载体（VP）、非病毒载体（NVP）、脂质纳米颗粒（LNP）、病毒样颗粒（VLP）在不同应用领域的选择，基因疗法与mRNA疫苗的创新发展动态，以及mRNA疫苗较传统疫苗的优缺点分析、开发趋势与应用前景。他们还全面回顾了该领域从技术创新到临床应用的进展，并一致认为长期递送技术、体外细胞系技术依然是关键挑战。 细胞和基因疗法工艺的开发流程复杂且高度个性化，这些特性被视为是阻碍这类疗法持续供应的重要挑战。随后的《细胞与基因疗法开发及生产中的CMC挑战》圆桌讨论环节，蓬勃生物欧洲商务拓展高级总监Qingyu Cao博士、JDB BioConsulting首席执行官Jim Faulkner博士、Leucid Bio CMC总监Arindam Mitra、Minaret Consulting Limited总监Dima AI-hadithi博士以及Smarter Biotech Solutions首席执行官Ming Ewe等讲者们展开了热烈讨论，提出了实用的策略和解决方案，为实现CGT的广泛应用提供了重要的参考。 “细胞与基因疗法开发及生产中的CMC挑战”圆桌讨论现场 他们认为，加速审批路径的推行给CMC时间安排带来较大压力，建议提前规划CMC与监管战略，以确保产品开发与质量控制能够并行不悖，并选择合适的CDMO合作伙伴以支持全程合作。同时，他们强调了可比性验证的重要性，提出应在研发初期就着手进行，并积极与监管机构沟通，以增进对新技术、新方法的理解，还应当绘制清晰的供应链图谱，以确保稳定供应。 谈及未来发展趋势，专家们认为AI技术将在优化基因疗法设计、提高生产效率以及推动自动化进程方面发挥重要作用。他们相信，随着技术的不断成熟和市场竞争的加剧，CGT疗法的价格将逐渐下降，有望成为一种普及的治疗方式。 细胞与基因治疗领域的研发和生产需要巨额资金投入，且回报周期较长。因此，资金压力也成为制约该领域发展的一个重要因素。论坛的压轴环节《投资者洞见：细胞与基因治疗的未来展望》炉边谈话中，投资界领袖Jefferies LLC高级副总裁Kelly Shi博士与RA Capital Management高级常务董事Josh Resnick、Stifel医疗保健领域投资银行部常务董事Ping Shek分享了各自在CGT领域的投资心得，回顾了该领域从早期热潮到当前调整期的演变。在投资策略的制定上，与会嘉宾指出，解决患者实际需求、减少研发及生产的不确定性，以及提高商业化成功率是核心考量因素，同时，他们也强调了在降低制造成本方面仍需积极探寻新的创新途径。 “投资者洞见：细胞与基因治疗的未来展望” 炉边谈话现场 在CGT投资趋势分析方面，尽管市场经历了波动，但2023年已初现复苏曙光，预示着未来资本流入的前景乐观。当前，投资行为趋于审慎，市场正稳步向常态化发展迈进。此外，监管环境的演变及报销政策的调整对投资决策产生了深远的影响，而解决基础设施建设和疗法可及性问题，则被视为推动该行业持续发展的核心动力。 金斯瑞生物科技全球产业论坛在各位专家学者们精彩的讨论中圆满落幕。这场盛会汇集了全球生物医药行业精英，大家聚在一起为行业发展提供宝贵经验和独到见解，为全球细胞基因治疗产业的持续发展和创新注入了新的动力。未来，金斯瑞生物科技将继续致力于搭建更加开放、包容的合作平台，推动细胞基因治疗领域的创新与发展。作为一项年度盛事，金斯瑞全球产业论坛将继续秉持“以患者为核心”的初衷，推动细胞和基因治疗的科研创新和市场应用，让全球健康未来更有希望。 关于金斯瑞生物科技 金斯瑞生物科技股份有限公司（HK.1548）是全球领先的生命科学研发与生产服务商。植根于坚实的DNA合成技术，金斯瑞现已建立四大主要业务单元：生命科学服务及产品业务单元、生物制剂合约开发及生产（CDMO）业务单元、工业合成产品业务单元及细胞疗法业务单元。自2002年成立以来，金斯瑞携手合作伙伴，加速推动科学发现与疗法突破，业务运营范围已覆盖全球100多个国家和地区，为20余万客户提供优质服务和产品。金斯瑞在全球现有5060名员工。截至2024年6月30日，全球范围已有超过100,000篇经国际同业审阅的学术期刊文献引述了金斯瑞的服务及产品。秉承“用生物技术使人和自然更健康”的企业使命，金斯瑞致力于成为全球“最受信赖的生物科技公司”。 更多信息，请访问金斯瑞官网https://www.genscript.com.cn/

LONDON, Nov. 21, 2024 /PRNewswire/ -- GenScript Biotech Corporation, a global leader in life sciences R&D and manufacturing services, successfully hosted the European debut of its GenScript Biotech Global Forum in London, UK. Since its inaugural session at the J.P. Morgan Healthcare Conference in San Francisco in 2020, the forum has become a significant platform for advancing cell and gene therapy (CGT). This year's move to Europe underscores GenScript's commitment to driving the global CGT innovation and fostering international collaboration. "Putting patients first" is the underlying principle driving progress in the pharmaceutical industry and the inspiration behind this year's forum. "All our efforts in creating this platform for open dialogue and international collaboration in the CGT industry ultimately aim to address patient needs," said Jesse Chen, VP of Government Affairs and Corporate Communications at GenScript, in a pre-event interview. The forum brought together global thought leaders from academia, industry, and investment sectors in CGT to explore the theme "Unlock the Full Potential of Cell and Gene Therapies." Discussions focused on the latest breakthroughs, technological innovations, and future trends, offering multi-dimensional perspectives on advancing the CGT industry to benefit more patients. The forum was moderated by Dr. Shawn Wu, President of European Division at GenScript. Sherry Shao, Rotating CEO of GenScript, delivered the opening remarks, emphasizing: "Every step forward in CGT, every innovation, is ultimately about serving patients better." She reaffirmed GenScript's commitment to driving innovation in CGT and collaborating with global partners to bring life-changing therapies to more patients worldwide. The forum featured two keynote sessions with distinguished speakers: Dr. Miguel Forte, President of the International Society for Cell & Gene Therapy (ISCT), ARM Board Member, and CEO of Kiji Therapeutics, and Dr. James Wilson, a pioneer in gene therapy and President & CEO of Gemma Biotherapeutics (GEMMABio); Founder and Advisor of Scout Bio, Passage Bio, iECURE; Executive Chair at Franklin Biolabs. Their thought-provoking presentations not only deepened attendees' understanding of the field but also offered valuable insights into the future of cell and gene therapy (CGT). Dr. Forte's delivered a keynote titled "Status and Expectations for Cell and Gene Therapy in 2024 and Beyond," focused on the transformative potential of cell therapy. He delved into gene editing, in vivo therapies, and the challenges and opportunities associated with regulatory approval. He emphasized the importance of understanding the long-term nature of cell therapy development and the significance of global collaboration. Dr. Wilson's keynote, "The Case for Rare Diseases in Genetic Medicine Development," He emphasized the importance of gene therapy for rare diseases and elaborated on the commercialization challenges of gene therapy products and discussed issues encountered in clinical development, such as technological shortcomings, the complexity of clinical trials, and production challenges. Dr. Wilson also emphasized the importance of patient advocacy and social media in promoting drug accessibility and raising public awareness. Additionally, he highlighted the need to focus on reimbursement mechanisms and achieve a balance between innovation and the resource utilization of health authorities. In addition to the compelling keynote speeches, the forum featured a range of dynamic interactive sessions, including three roundtable discussions and a fireside chat. These sessions attracted significant attention, offering lively debates and actionable insights that resonated with the audience. The success of CAR-T therapies in hematologic malignancies has revealed the vast potential of cell therapies. Now, the focus is on extending these breakthroughs to broader patient populations, including those with solid tumors and autoimmune diseases, which have become a shared goal across the industry. During the "Technology Innovation and Breakthroughs in Cell Therapy" roundtable, Mr. Stephen Hansen, Director of Biopharma Intelligence at BioCentury, moderated a vibrant discussion featuring leaders such as Dr. Ying Huang, CEO of Legend Biotech, Dr. Reagan Jarvis, CEO and Co-founder of Anocca, Dr. Pascal Touchon, Chairman of the Board at Atara Biotherapeutics, Mr. Jason Foster, CEO and Executive Director of Ori Biotech, and Dr. Biao Zheng, CEO of BRL Medicine. They approached the topic from the patient's perspective, highlighting the exceptional efficacy of CAR-T therapy. The experts also shared promising clinical data on the use of CAR-T drugs for autoimmune diseases and expressed high hopes for their future development. They emphasized that developing more patient-friendly, user-friendly CAR-T therapies is critical for increasing patient acceptance. Additionally, expanding production capacity, improving product accessibility, and ensuring product safety are urgent priorities. Collaboration with medical centers is key to developing commercially viable products. As innovative therapies continue to be researched, the potential applications of CAR-T therapy will be further unlocked, offering patients more treatment options. Driven by technological breakthroughs, significant progress has been made in gene therapy and mRNA vaccine fields, with applications expanding rapidly. However, the production of these therapies is complex, particularly when it comes to the choice, production, and optimization of delivery vectors, which have a profound impact on their development. In the roundtable discussion on "Progress in Gene Therapy and mRNA Vaccine," hosted by Ms. Kristina Cornish, Partner at Pinsent Masons, London & European and UK Patent Attorney, leading researchers including Mr. Deividas Pazeraitis, Senior Scientist at AstraZeneca, Dr. Karim Benabdellah, Principal Investigator at GENYO, Dr. Maelle Quere, Scientist at Sanofi, Dr. Vincenzo Di Cerbo, Lead Technical Scientist at Cell and Gene Therapy Catapult, and Dr. Lumeng Ye, Director of Novel therapeutic materials at GenScript; all agreed that long-term delivery efficiency and technological bottlenecks remain key challenges in translating innovations into clinical applications. The discussion focused on the technological trends and innovative developments in the clinical applications of gene editing, the topics cover the selection of viral vectors (VP), non-viral vectors (NVP), lipid nanoparticles (LNP), and virus-like particles (VLP) in different application areas, the innovative developments in gene therapy and mRNA vaccines, as well as an analysis of the advantages and disadvantages of mRNA vaccines compared to traditional vaccines, along with development trends and application prospects. They also provided a comprehensive review of the progress from technological innovation to clinical application in this field and unanimously agreed that long-term delivery technology and in vitro cell line technology remain key challenges. The development process for CGT is highly complex and personalized, and these characteristics are seen as major challenges to the continuous supply of these therapies. In the subsequent roundtable discussion on "CMC Challenges with Developing & Manufacturing Cell and Gene Therapies," led by Dr. Qingyu Cao, Senior Director & head of European Business Development at ProBio, and panelists are Dr. Jim Faulkner, CEO of JDB BioConsulting, Mr. Arindam Mitra, CMC Director at Leucid Bio, Dr. Dima Al-hadithi, Director at Minaret Consulting Limited, and Ms. Ming Ewe, CEO of Smarter Biotech Solutions, engaged in lively discussions on key issues such as production process standardization, quality control, and viral vector production. The discussion presented practical strategies and solutions, providing important references for the widespread application of CGT. The experts emphasized the need for early planning of CMC and regulatory strategies in the context of accelerated approval processes, ensuring that product development and quality control can proceed in parallel. They also highlighted the importance of selecting the right CDMO partners to support full collaboration. Furthermore, they suggested that efforts should begin early in the R&D phase, with active communication with regulatory agencies to enhance the understanding of new technologies and methods, and a clear supply chain map should be created to ensure stable supply. Regarding future trends, the experts believe that AI technology will play a key role in optimizing gene therapy design, improving production efficiency, and advancing automation processes. They are confident that, with ongoing technological advancements and increasing market competition, the price of CGT therapies will gradually decrease, making them a widely accessible treatment option. R&D and manufacturing in the cell and gene therapy field require substantial financial investment, with long return cycles, making funding pressure a key constraint on industry growth. In the closing fireside chat, "Navigating the Future of CGT: Insights from Investors," was moderated by Dr. Kelly Shi, Senior VP & Research Analys at Jefferies LLC, Dr. Josh Resnick, Senior Managing Director at RA Capital Management, and Mr. Ping Shek, Managing Director at Stifel's Investment Banking Division, discussed the investment landscape for CGT. The speakers shared their investment insights in the CGT field, reviewing the evolution of the sector from its early boom to the current adjustment phase. When discussing investment strategies, the participants highlighted key considerations such as addressing patient needs, reducing uncertainty in research and development as well as manufacturing, and increasing commercialization success rates. They also emphasized the need for continued innovation in reducing manufacturing costs. Regarding the investment trend in CGT, despite market fluctuations, signs of recovery began to emerge in 2023, indicating a positive outlook for future capital inflows. Currently, investment behavior is becoming more cautious, and the market is steadily moving toward normalization. Furthermore, the evolving regulatory environment and changes in reimbursement policies have had a profound impact on investment decisions. Addressing infrastructure development and therapy accessibility is viewed as a core driver for the sustained growth of the industry. The GenScript Biotech Global Forum concluded successfully with engaging discussions from experts and scholars. This event brought together global leaders from the biopharmaceutical industry, who shared valuable experiences and unique insights, injecting fresh momentum into the continued development and innovation of the global cell and gene therapy sector. Moving forward, GenScript Biotech remains committed to building more open and inclusive collaboration platforms to drive innovation and progress in the field of cell and gene therapy. As an annual event, the GenScript Global Forum will continue to uphold its core focus of "patient-centered" goals, advancing scientific innovation and market applications in cell and gene therapies, bringing greater hope for a healthier global future. About GenScript Biotech Corporation GenScript Biotech Corporation (HK.1548) is a world leader in technologies and services for life science R&D and manufacture. Built upon its solid DNA synthesis technology, the company comprises four major business units: a life-science services and products business unit, a biologics contract development and manufacturing organization (CDMO) business unit, an industrial synthetic products business unit, and Cell Therapy Business Unit. GenScript accelerates scientific discovery and therapeutic breakthrough with its customers. Since its founding in New Jersey, USA in 2002, GenScript has expanded its operations to serve more than 200,000 customers across 100 countries with a dedicated team of 5060 employees. As of June 30, 2024, over 100,000 peer-reviewed journal articles worldwide had cited GenScript 's services and products. Guided by its mission to make people and nature healthier through biotechnology, GenScript strives to become the most trustworthy biotech company in the world. For more information, please visit GenScript Biotech's official website SOURCE GenScript Biotech Corporation WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED